{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:10:20Z","timestamp":1792285820690,"version":"4.4.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasitol Res"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00436-022-07659-5","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T05:03:31Z","timestamp":1663304611000},"page":"3073-3082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Liposomal drug delivery systems for the treatment of leishmaniasis"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3471-1786","authenticated-orcid":false,"given":"Felipe Francisco","family":"Tuon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia Ramos","family":"Dantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7650-9968","authenticated-orcid":false,"given":"Regina Maia","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-3598","authenticated-orcid":false,"given":"Victoria Stadler Tasca","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1245-9348","authenticated-orcid":false,"given":"Valdir Sabbaga","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"issue":"2","key":"7659_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/ddr.21664","volume":"83","author":"F Altamura","year":"2022","unstructured":"Altamura F, Rajesh R, Catta-Preta CMC, Moretti NS, Cestari I (2022) The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets. Drug Dev Res 83(2):225\u2013252. https:\/\/doi.org\/10.1002\/ddr.21664","journal-title":"Drug Dev Res"},{"issue":"5","key":"7659_CR2","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar J et al (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7(5):e35671. https:\/\/doi.org\/10.1371\/journal.pone.0035671","journal-title":"PLoS ONE"},{"issue":"1","key":"7659_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actatropica.2007.08.003","volume":"105","author":"VS Amato","year":"2008","unstructured":"Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC (2008) Mucosal leishmaniasis Current scenario and prospects for treatment. Acta Trop 105(1):1\u20139. https:\/\/doi.org\/10.1016\/j.actatropica.2007.08.003","journal-title":"Acta Trop"},{"issue":"5","key":"7659_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4269\/ajtmh.2011.11-0287","volume":"85","author":"VS Amato","year":"2011","unstructured":"Amato VS, Tuon FF, Camargo RA, Souza RM, Santos CR, Nicodemo AC (2011) Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 85(5):818\u2013819. https:\/\/doi.org\/10.4269\/ajtmh.2011.11-0287","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"7659_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1086\/510494","volume":"44","author":"VS Amato","year":"2007","unstructured":"Amato VS et al (2007) Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin Infect Dis 44(2):311\u2013312. https:\/\/doi.org\/10.1086\/510494","journal-title":"Clin Infect Dis"},{"issue":"10","key":"7659_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.1365-4632.2009.04099.x","volume":"48","author":"VS Amato","year":"2009","unstructured":"Amato VS et al (2009) Immunohistochemistry and polymerase chain reaction on paraffin-embedded material improve the diagnosis of cutaneous leishmaniasis in the Amazon region. Int J Dermatol 48(10):1091\u20131095. https:\/\/doi.org\/10.1111\/j.1365-4632.2009.04099.x","journal-title":"Int J Dermatol"},{"issue":"9","key":"7659_CR7","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/j.1468-3083.2009.03238.x","volume":"23","author":"VS Amato","year":"2009","unstructured":"Amato VS, Tuon FF, Imamura R, Abegao de Camargo R, Duarte MI, Neto VA (2009) Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 23(9):1026\u20131034. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03238.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"7659_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4269\/ajtmh.2007.77.266","volume":"77","author":"VS Amato","year":"2007","unstructured":"Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA (2007) Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 77(2):266\u2013274","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"7659_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12639-014-0529-0","volume":"40","author":"EI Amer","year":"2016","unstructured":"Amer EI, Eissa MM, Mossallam SF (2016) Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis. J Parasit Dis 40(2):475\u2013484. https:\/\/doi.org\/10.1007\/s12639-014-0529-0","journal-title":"J Parasit Dis"},{"issue":"10","key":"7659_CR10","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1517\/17425247.2014.932347","volume":"11","author":"EG Azevedo","year":"2014","unstructured":"Azevedo EG et al (2014) Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis. Expert Opin Drug Deliv 11(10):1551\u20131560. https:\/\/doi.org\/10.1517\/17425247.2014.932347","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"7659_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.trstmh.2010.11.010","volume":"105","author":"HA Bacha","year":"2011","unstructured":"Bacha HA et al (2011) Leishmania (Viannia) braziliensis identification by PCR in the state of Para, Brazil. Trans R Soc Trop Med Hyg 105(3):173\u2013178. https:\/\/doi.org\/10.1016\/j.trstmh.2010.11.010","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6","key":"7659_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/1566524043360186","volume":"4","author":"MK Basu","year":"2004","unstructured":"Basu MK, Lala S (2004) Macrophage specific drug delivery in experimental leishmaniasis. Curr Mol Med 4(6):681\u2013689. https:\/\/doi.org\/10.2174\/1566524043360186","journal-title":"Curr Mol Med"},{"issue":"7","key":"7659_CR13","doi-asserted-by":"publisher","first-page":"e2982","DOI":"10.1371\/journal.pntd.0002982","volume":"8","author":"VS Belo","year":"2014","unstructured":"Belo VS et al (2014) Risk factors for adverse prognosis and death in American visceral leishmaniasis: a meta-analysis. PLoS Negl Trop Dis 8(7):e2982. https:\/\/doi.org\/10.1371\/journal.pntd.0002982","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"7659_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1128\/AAC.27.6.916","volume":"27","author":"JD Berman","year":"1985","unstructured":"Berman JD, Waddell D, Hanson BD (1985) Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother 27(6):916\u2013920. https:\/\/doi.org\/10.1128\/AAC.27.6.916","journal-title":"Antimicrob Agents Chemother"},{"key":"7659_CR15","doi-asserted-by":"publisher","unstructured":"Borborema SE, Schwendener RA, Osso JA Jr, de Andrade HF Jr, do Nascimento N (2011) Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages. Int J Antimicrob Agents 38(4):341\u2013347. https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.05.012","DOI":"10.1016\/j.ijantimicag.2011.05.012"},{"key":"7659_CR16","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.biopha.2018.05.004","volume":"103","author":"SET Borborema","year":"2018","unstructured":"Borborema SET, Osso Junior JA, Tempone AG, de Andrade Junior HF, do Nascimento N (2018) Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis. Biomed Pharmacother 103:1609\u20131616. https:\/\/doi.org\/10.1016\/j.biopha.2018.05.004","journal-title":"Biomed Pharmacother"},{"issue":"10151","key":"7659_CR17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","volume":"392","author":"S Burza","year":"2018","unstructured":"Burza S, Croft SL, Boelaert M (2018) Leishmaniasis Lancet 392(10151):951\u2013970. https:\/\/doi.org\/10.1016\/S0140-6736(18)31204-2","journal-title":"Leishmaniasis Lancet"},{"key":"7659_CR18","doi-asserted-by":"publisher","unstructured":"Calvo A, Moreno E, Larrea E, Sanmartin C, Irache JM, Espuelas S (2020) Berberine-loaded liposomes for the treatment of leishmania infantum-infected BALB\/c mice. Pharmaceutics 12(9):858. https:\/\/doi.org\/10.3390\/pharmaceutics12090858","DOI":"10.3390\/pharmaceutics12090858"},{"issue":"3","key":"7659_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4269\/ajtmh.2010.10-0081","volume":"83","author":"RA Camargo","year":"2010","unstructured":"Camargo RA et al (2010) Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses. Am J Trop Med Hyg 83(3):515\u2013518. https:\/\/doi.org\/10.4269\/ajtmh.2010.10-0081","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"7659_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/08982100903015025","volume":"20","author":"G Carneiro","year":"2010","unstructured":"Carneiro G et al (2010) Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res 20(1):16\u201323. https:\/\/doi.org\/10.3109\/08982100903015025","journal-title":"J Liposome Res"},{"key":"7659_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ejpb.2015.04.018","volume":"93","author":"M Carvalheiro","year":"2015","unstructured":"Carvalheiro M et al (2015) Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections. Eur J Pharm Biopharm 93:346\u2013352. https:\/\/doi.org\/10.1016\/j.ejpb.2015.04.018","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"7659_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/s0020-7519(00)00053-9","volume":"30","author":"E Cauchetier","year":"2000","unstructured":"Cauchetier E, Paul M, Rivollet D, Fessi H, Astier A, Deniau M (2000) Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis. Int J Parasitol 30(6):777\u2013783. https:\/\/doi.org\/10.1016\/s0020-7519(00)00053-9","journal-title":"Int J Parasitol"},{"issue":"4971","key":"7659_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1126\/science.2392684","volume":"249","author":"MM Chan","year":"1990","unstructured":"Chan MM, Fong D (1990) Inhibition of leishmanias but not host macrophages by the antitubulin herbicide trifluralin. Science 249(4971):924\u2013926. https:\/\/doi.org\/10.1126\/science.2392684","journal-title":"Science"},{"issue":"6","key":"7659_CR24","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/jac\/dkp117","volume":"63","author":"MJ Chan-Bacab","year":"2009","unstructured":"Chan-Bacab MJ, Hernandez-Nunez E, Navarrete-Vazquez G (2009) Nitazoxanide, tizoxanide and a new analogue [4-nitro-N-(5-nitro-1,3-thiazol-2-yl)benzamide; NTB] inhibit the growth of kinetoplastid parasites (Trypanosoma cruzi and Leishmania mexicana) in vitro. J Antimicrob Chemother 63(6):1292\u20131293. https:\/\/doi.org\/10.1093\/jac\/dkp117","journal-title":"J Antimicrob Chemother"},{"issue":"14","key":"7659_CR25","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1016\/j.bmc.2018.06.033","volume":"26","author":"J Cogo","year":"2018","unstructured":"Cogo J et al (2018) Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents. Bioorg Med Chem 26(14):4065\u20134072. https:\/\/doi.org\/10.1016\/j.bmc.2018.06.033","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"7659_CR26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1128\/CVI.00338-14","volume":"21","author":"N Craft","year":"2014","unstructured":"Craft N et al (2014) Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice. Clin Vaccine Immunol 21(9):1314\u20131322. https:\/\/doi.org\/10.1128\/CVI.00338-14","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"7659_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/jac\/30.6.827","volume":"30","author":"SL Croft","year":"1992","unstructured":"Croft SL, Hogg J, Gutteridge WE, Hudson AT, Randall AW (1992) The activity of hydroxynaphthoquinones against Leishmania donovani. J Antimicrob Chemother 30(6):827\u2013832. https:\/\/doi.org\/10.1093\/jac\/30.6.827","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"7659_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"SL Croft","year":"2006","unstructured":"Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19(1):111\u2013126. https:\/\/doi.org\/10.1128\/CMR.19.1.111-126.2006","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"7659_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/02652048.2015.1046518","volume":"32","author":"TA Cury","year":"2015","unstructured":"Cury TA et al (2015) Cinnamic acid derived compounds loaded into liposomes: antileishmanial activity, production standardisation and characterisation. J Microencapsul 32(5):467\u2013477. https:\/\/doi.org\/10.3109\/02652048.2015.1046518","journal-title":"J Microencapsul"},{"issue":"1","key":"7659_CR30","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1080\/10717544.2018.1494222","volume":"25","author":"MJ Dar","year":"2018","unstructured":"Dar MJ, Din FU, Khan GM (2018) Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell. Drug Deliv 25(1):1595\u20131606. https:\/\/doi.org\/10.1080\/10717544.2018.1494222","journal-title":"Drug Deliv"},{"key":"7659_CR31","doi-asserted-by":"publisher","first-page":"105256","DOI":"10.1016\/j.ejps.2020.105256","volume":"145","author":"MJ Dar","year":"2020","unstructured":"Dar MJ, Khalid S, Varikuti S, Satoskar AR, Khan GM (2020) Nano-elastic liposomes as multidrug carrier of sodium stibogluconate and ketoconazole: A potential new approach for the topical treatment of cutaneous Leishmaniasis. Eur J Pharm Sci 145:105256. https:\/\/doi.org\/10.1016\/j.ejps.2020.105256","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"7659_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1166\/jbn.2017.2349","volume":"13","author":"L de Almeida","year":"2017","unstructured":"de Almeida L et al (2017) Nanotechnological Strategies for Treatment of Leishmaniasis\u2013A Review. J Biomed Nanotechnol 13(2):117\u2013133. https:\/\/doi.org\/10.1166\/jbn.2017.2349","journal-title":"J Biomed Nanotechnol"},{"key":"7659_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.intimp.2016.04.025","volume":"36","author":"NB de Barros","year":"2016","unstructured":"de Barros NB et al (2016) Liposomes containing an ASP49-phospholipase A2 from Bothrops jararacussu snake venom as experimental therapy against cutaneous leishmaniasis. Int Immunopharmacol 36:225\u2013231. https:\/\/doi.org\/10.1016\/j.intimp.2016.04.025","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"7659_CR34","doi-asserted-by":"publisher","first-page":"e3001","DOI":"10.1371\/journal.pntd.0003001","volume":"8","author":"RA de Camargo","year":"2014","unstructured":"de Camargo RA et al (2014) Facial structure alterations and abnormalities of the paranasal sinuses on multidetector computed tomography scans of patients with treated mucosal leishmaniasis. PLoS Negl Trop Dis 8(7):e3001. https:\/\/doi.org\/10.1371\/journal.pntd.0003001","journal-title":"PLoS Negl Trop Dis"},{"key":"7659_CR35","doi-asserted-by":"publisher","unstructured":"Dos Santos CCP, Ramos GS, De Paula RC, Faria KF, Moreira POL, Pereira RA, Melo MN, Tafuri WL, Demicheli C, Ribeiro RR, Azevedo EG, Monte-Neto RD, Da Silva SM, Fr\u00e9zard F (2020) Therapeutic efficacy of a mixed formulation of conventional and\u00a0pegylated liposomes\u00a0containing meglumine antimoniate, combined with allopurinol, in dogs naturally infected with leishmania infantum. Antimicrob Agents Chemother 64(7):e00234-20. https:\/\/doi.org\/10.1128\/AAC.00234-20","DOI":"10.1128\/AAC.00234-20"},{"issue":"sup2","key":"7659_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1080\/21691401.2018.1457042","volume":"46","author":"T Emami","year":"2018","unstructured":"Emami T et al (2018) The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB\/c mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome. Artif Cells Nanomed Biotechnol 46(sup2):324\u2013333. https:\/\/doi.org\/10.1080\/21691401.2018.1457042","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"10","key":"7659_CR37","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1080\/10826068.2021.1885045","volume":"51","author":"A Fattahi Bafghi","year":"2021","unstructured":"Fattahi Bafghi A, Haghirosadat BF, Yazdian F, Mirzaei F, Pourmadadi M, Pournasir F, Hemati M, Pournasir S (2021) A novel delivery of curcumin by the efficient nanoliposomal approach against Leishmania major. Prep Biochem Biotechnol 51(10):990\u2013997. https:\/\/doi.org\/10.1080\/10826068.2021.1885045","journal-title":"Prep Biochem Biotechnol"},{"issue":"2","key":"7659_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00436-013-3685-8","volume":"113","author":"FM Ferreira","year":"2014","unstructured":"Ferreira FM et al (2014) Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis. Parasitol Res 113(2):533\u2013543. https:\/\/doi.org\/10.1007\/s00436-013-3685-8","journal-title":"Parasitol Res"},{"issue":"3","key":"7659_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1081\/ddc-120030423","volume":"30","author":"LS Ferreira","year":"2004","unstructured":"Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA (2004) In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm 30(3):289\u2013296. https:\/\/doi.org\/10.1081\/ddc-120030423","journal-title":"Drug Dev Ind Pharm"},{"key":"7659_CR40","doi-asserted-by":"publisher","first-page":"e0305","DOI":"10.1590\/0037-8682-0305-2020","volume":"54","author":"G Fuentes-Nava","year":"2021","unstructured":"Fuentes-Nava G, Tirado-Sanchez A, Fernandez-Figueroa EA, Sanchez-Montes S, Becker I, Bonifaz A (2021) Efficacy of imiquimod 5% cream as first-line management in cutaneous leishmaniasis caused by Leishmania mexicana. Rev Soc Bras Med Trop 54:e0305-2020. https:\/\/doi.org\/10.1590\/0037-8682-0305-2020","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3","key":"7659_CR41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1751-1097.2010.00705.x","volume":"86","author":"DM Gardner","year":"2010","unstructured":"Gardner DM et al (2010) Association of acenaphthoporphyrins with liposomes for the photodynamic treatment of leishmaniasis. Photochem Photobiol 86(3):645\u2013652. https:\/\/doi.org\/10.1111\/j.1751-1097.2010.00705.x","journal-title":"Photochem Photobiol"},{"issue":"1","key":"7659_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40249-018-0491-7","volume":"7","author":"EA Gebreyohannes","year":"2018","unstructured":"Gebreyohannes EA, Bhagvathula AS, Abegaz TM, Seid MA (2018) Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis. Infect Dis Poverty 7(1):108. https:\/\/doi.org\/10.1186\/s40249-018-0491-7","journal-title":"Infect Dis Poverty"},{"issue":"Suppl 1","key":"7659_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/tbed.13312","volume":"67","author":"M Gharbi","year":"2020","unstructured":"Gharbi M et al (2020) Current status of tropical theileriosis in Northern Africa: A review of recent epidemiological investigations and implications for control. Transbound Emerg Dis 67(Suppl 1):8\u201325. https:\/\/doi.org\/10.1111\/tbed.13312","journal-title":"Transbound Emerg Dis"},{"key":"7659_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4612-2302-3_1","volume":"153","author":"R Grover","year":"1997","unstructured":"Grover R, Wolt JD, Cessna AJ, Schiefer HB (1997) Environmental fate of trifluralin. Rev Environ Contam Toxicol 153:1\u201364. https:\/\/doi.org\/10.1007\/978-1-4612-2302-3_1","journal-title":"Rev Environ Contam Toxicol"},{"issue":"3","key":"7659_CR45","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13346-019-00631-4","volume":"9","author":"Z Hussain","year":"2019","unstructured":"Hussain Z, Khan S, Imran M, Sohail M, Shah SWA, de Matas M (2019) PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution. Drug Deliv Transl Res 9(3):721\u2013734. https:\/\/doi.org\/10.1007\/s13346-019-00631-4","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"7659_CR46","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S1473-3099(16)00003-7","volume":"16","author":"C Karimkhani","year":"2016","unstructured":"Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M (2016) Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 16(5):584\u2013591. https:\/\/doi.org\/10.1016\/S1473-3099(16)00003-7","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"7659_CR47","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1473-3099(16)30217-1","volume":"17","author":"C Karimkhani","year":"2017","unstructured":"Karimkhani C, Wanga V, Naghavi P, Dellavalle RP, Naghavi M (2017) Global burden of cutaneous leishmaniasis. Lancet Infect Dis 17(3):264. https:\/\/doi.org\/10.1016\/S1473-3099(16)30217-1","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"7659_CR48","first-page":"90","volume":"27","author":"EA Khalil","year":"2006","unstructured":"Khalil EA, Ahmed AE, Musa AM, Hussein MH (2006) Antimony-induced cerebellar ataxia. Saudi Med J 27(1):90\u201392","journal-title":"Saudi Med J"},{"issue":"3","key":"7659_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/10611860410001712696","volume":"12","author":"S Lala","year":"2004","unstructured":"Lala S, Pramanick S, Mukhopadhyay S, Bandyopadhyay S, Basu MK (2004) Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J Drug Target 12(3):165\u2013175. https:\/\/doi.org\/10.1080\/10611860410001712696","journal-title":"J Drug Target"},{"issue":"7","key":"7659_CR50","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s0167-7799(98)01220-7","volume":"16","author":"DD Lasic","year":"1998","unstructured":"Lasic DD (1998) Novel applications of liposomes. Trends Biotechnol 16(7):307\u2013321. https:\/\/doi.org\/10.1016\/s0167-7799(98)01220-7","journal-title":"Trends Biotechnol"},{"issue":"2","key":"7659_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2217\/nnm.15.190","volume":"11","author":"RM Lopes","year":"2016","unstructured":"Lopes RM et al (2016) Lipid-based nanoformulations of trifluralin analogs in the management of Leishmania infantum infections. Nanomedicine (lond) 11(2):153\u2013170. https:\/\/doi.org\/10.2217\/nnm.15.190","journal-title":"Nanomedicine (lond)"},{"issue":"1","key":"7659_CR52","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1021\/jm030868a","volume":"47","author":"A Mantyla","year":"2004","unstructured":"Mantyla A et al (2004) Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J Med Chem 47(1):188\u2013195. https:\/\/doi.org\/10.1021\/jm030868a","journal-title":"J Med Chem"},{"issue":"2","key":"7659_CR53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.eimc.2020.04.005","volume":"39","author":"I Marti-Marti","year":"2021","unstructured":"Marti-Marti I, Alsina M, Giavedoni P, Fuertes I (2021) Cutaneous leishmaniasis of the face treated with imiquimod 3.75. Enferm Infecc Microbiol Clin (Engl Ed) 39(2):108\u2013109. https:\/\/doi.org\/10.1016\/j.eimc.2020.04.005","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"issue":"4","key":"7659_CR54","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S1473-3099(10)70320-0","volume":"11","author":"G Matlashewski","year":"2011","unstructured":"Matlashewski G et al (2011) Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis 11(4):322\u2013325. https:\/\/doi.org\/10.1016\/S1473-3099(10)70320-0","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"7659_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0034-5288(18)31765-X","volume":"39","author":"N McHardy","year":"1985","unstructured":"McHardy N, Wekesa LS, Hudson AT, Randall AW (1985) Antitheilerial activity of BW720C (buparvaquone): a comparison with parvaquone. Res Vet Sci 39(1):29\u201333","journal-title":"Res Vet Sci"},{"issue":"6","key":"7659_CR56","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/jac\/44.6.791","volume":"44","author":"S Medda","year":"1999","unstructured":"Medda S, Mukhopadhyay S, Basu MK (1999) Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J Antimicrob Chemother 44(6):791\u2013794. https:\/\/doi.org\/10.1093\/jac\/44.6.791","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"7659_CR57","doi-asserted-by":"publisher","first-page":"e0008947","DOI":"10.1371\/journal.pntd.0008947","volume":"14","author":"H Medkour","year":"2020","unstructured":"Medkour H et al (2020) Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial. PLoS Negl Trop Dis 14(12):e0008947. https:\/\/doi.org\/10.1371\/journal.pntd.0008947","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"7659_CR58","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.actatropica.2013.09.018","volume":"128","author":"JT Mesquita","year":"2013","unstructured":"Mesquita JT, Pinto EG, Taniwaki NN, Galisteo AJ Jr, Tempone AG (2013) Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative stress in Leishmania (L.) infantum. Acta Trop 128(3):666\u201373. https:\/\/doi.org\/10.1016\/j.actatropica.2013.09.018","journal-title":"Acta Trop"},{"issue":"1","key":"7659_CR59","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/INF.0b013e3181506683","volume":"27","author":"P Minodier","year":"2008","unstructured":"Minodier P, Zambelli L, Mary C, Faraut F, Garnier JM, Berbis P (2008) Cutaneous leishmaniasis treated with azithromycin in a child. Pediatr Infect Dis J 27(1):80\u201381. https:\/\/doi.org\/10.1097\/INF.0b013e3181506683","journal-title":"Pediatr Infect Dis J"},{"key":"7659_CR60","doi-asserted-by":"publisher","first-page":"9781603","DOI":"10.1155\/2017\/9781603","volume":"2017","author":"LM Monteiro","year":"2017","unstructured":"Monteiro LM, Lobenberg R, Cotrim PC, Barros de Araujo GL, Bou-Chacra N (2017) Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases. Biomed Res Int 2017:9781603. https:\/\/doi.org\/10.1155\/2017\/9781603","journal-title":"Biomed Res Int"},{"key":"7659_CR61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.exppara.2019.03.004","volume":"200","author":"SA Moosavian","year":"2019","unstructured":"Moosavian SA, Fallah M, Jaafari MR (2019) The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB\/c mice. Exp Parasitol 200:30\u201335. https:\/\/doi.org\/10.1016\/j.exppara.2019.03.004","journal-title":"Exp Parasitol"},{"issue":"5","key":"7659_CR62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/00034983.1988.11812275","volume":"82","author":"RA Neal","year":"1988","unstructured":"Neal RA, van Bueren J, Hooper G (1988) The activity of nitrofurazone and furazolidone against Leishmania donovani, L. major and L. enriettii in vitro and in vivo. Ann Trop Med Parasitol 82(5):453\u20136. https:\/\/doi.org\/10.1080\/00034983.1988.11812275","journal-title":"Ann Trop Med Parasitol"},{"issue":"3","key":"7659_CR63","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1590\/s0037-86822005000300011","volume":"38","author":"MC Oliveira","year":"2005","unstructured":"Oliveira MC, Amorim RF, Freitas Rde A, Costa Ade L (2005) A fatal case of mucocutaneous leishmaniasis after pentavalent antimonial use. Rev Soc Bras Med Trop 38(3):258\u2013260. https:\/\/doi.org\/10.1590\/s0037-86822005000300011","journal-title":"Rev Soc Bras Med Trop"},{"issue":"4","key":"7659_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2174\/156720105774370177","volume":"2","author":"M Owais","year":"2005","unstructured":"Owais M, Gupta CM (2005) Targeted drug delivery to macrophages in parasitic infections. Curr Drug Deliv 2(4):311\u2013318. https:\/\/doi.org\/10.2174\/156720105774370177","journal-title":"Curr Drug Deliv"},{"issue":"9","key":"7659_CR65","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1128\/AAC.48.9.3591-3593.2004","volume":"48","author":"S Pal","year":"2004","unstructured":"Pal S, Ravindran R, Ali N (2004) Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB\/c Mice. Antimicrob Agents Chemother 48(9):3591\u20133593. https:\/\/doi.org\/10.1128\/AAC.48.9.3591-3593.2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"7659_CR66","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ijantimicag.2014.07.011","volume":"44","author":"SR Passos","year":"2014","unstructured":"Passos SR, de Rodrigues TA, Madureira AP, Giunchetti RC, Zanini MS (2014) Clinical treatment of cutaneous leishmaniasis in dogs with furazolidone and domperidone. Int J Antimicrob Agents 44(5):463\u2013465. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.07.011","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"7659_CR67","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/jac\/dkt320","volume":"69","author":"KJ Peine","year":"2014","unstructured":"Peine KJ et al (2014) Liposomal resiquimod for the treatment of Leishmania donovani infection. J Antimicrob Chemother 69(1):168\u2013175. https:\/\/doi.org\/10.1093\/jac\/dkt320","journal-title":"J Antimicrob Chemother"},{"key":"7659_CR68","doi-asserted-by":"publisher","first-page":"109296","DOI":"10.1016\/j.cbi.2020.109296","volume":"332","author":"EG Pinto","year":"2020","unstructured":"Pinto EG, Barbosa LRS, Mortara RA, Tempone AG (2020) Targeting intracellular Leishmania (L.) infantum with nitazoxanide entrapped into phosphatidylserine-nanoliposomes: An experimental study. Chem Biol Interact 332:109296. https:\/\/doi.org\/10.1016\/j.cbi.2020.109296","journal-title":"Chem Biol Interact"},{"key":"7659_CR69","doi-asserted-by":"publisher","first-page":"8629039","DOI":"10.1155\/2021\/8629039","volume":"2021","author":"P Pokharel","year":"2021","unstructured":"Pokharel P, Ghimire R, Lamichhane P (2021) Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review. J Trop Med 2021:8629039. https:\/\/doi.org\/10.1155\/2021\/8629039","journal-title":"J Trop Med"},{"issue":"9","key":"7659_CR70","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1128\/AAC.45.9.2623-2627.2001","volume":"45","author":"ME Proulx","year":"2001","unstructured":"Proulx ME, Desormeaux A, Marquis JF, Olivier M, Bergeron MG (2001) Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother 45(9):2623\u20132627. https:\/\/doi.org\/10.1128\/AAC.45.9.2623-2627.2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"7659_CR71","first-page":"248","volume":"36","author":"B Raay","year":"1999","unstructured":"Raay B, Medda S, Mukhopadhyay S, Basu MK (1999) Targeting of piperine intercalated in mannose-coated liposomes in experimental leishmaniasis. Indian J Biochem Biophys 36(4):248\u2013251","journal-title":"Indian J Biochem Biophys"},{"issue":"5","key":"7659_CR72","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/dth.12357","volume":"29","author":"O Rajabi","year":"2016","unstructured":"Rajabi O, Layegh P, Hashemzadeh S, Khoddami M (2016) Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis. Dermatol Ther 29(5):358\u2013363. https:\/\/doi.org\/10.1111\/dth.12357","journal-title":"Dermatol Ther"},{"key":"7659_CR73","doi-asserted-by":"publisher","first-page":"111120","DOI":"10.1016\/j.biopha.2020.111120","volume":"134","author":"GS Ramos","year":"2021","unstructured":"Ramos GS et al (2021) Antileishmanial activity of fullerol and its liposomal formulation in experimental models of visceral leishmaniasis. Biomed Pharmacother 134:111120. https:\/\/doi.org\/10.1016\/j.biopha.2020.111120","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"7659_CR74","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.exppara.2012.01.010","volume":"130","author":"JQ Reimao","year":"2012","unstructured":"Reimao JQ, Colombo FA, Pereira-Chioccola VL, Tempone AG (2012) Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi. Exp Parasitol 130(3):195\u20139. https:\/\/doi.org\/10.1016\/j.exppara.2012.01.010","journal-title":"Exp Parasitol"},{"issue":"6","key":"7659_CR75","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00436-010-1826-x","volume":"106","author":"JQ Reimao","year":"2010","unstructured":"Reimao JQ, Taniwaki NN, Tempone AG (2010) Furazolidone is a selective in vitro candidate against Leishmania (L.) chagasi: an ultrastructural study. Parasitol Res 106(6):1465\u20139. https:\/\/doi.org\/10.1007\/s00436-010-1826-x","journal-title":"Parasitol Res"},{"key":"7659_CR76","doi-asserted-by":"publisher","unstructured":"Reis LES, de Brito RCF, de Oliveira Cardoso JM, Mathias FAS, Soares RDOA, Carneiro CM, de Abreu Vieira PM, Ramos GS, Fr\u00e9zard FJG, Roatt BM, Reis AB (2017) Mixed formulation of conventional and pegylated meglumine antimoniate-containing liposomes reduces inflammatory process and parasite burden in leishmania infantum-infected BALB\/c mice. Antimicrob Agents Chemother 61(11):e00962-17. https:\/\/doi.org\/10.1128\/AAC.00962-17","DOI":"10.1128\/AAC.00962-17"},{"issue":"4","key":"7659_CR77","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5740\/jaoacint.10-263","volume":"96","author":"PG Reis","year":"2013","unstructured":"Reis PG, Abreu AT, Guimaraes AG, Teixeira MC, de Souza J, Silva-Barcellos NM (2013) Development and validation of an analytical method for quantification of arsenic and antimony in liposomes using inductively coupled plasma-optical emission spectrometry. J AOAC Int 96(4):771\u2013775. https:\/\/doi.org\/10.5740\/jaoacint.10-263","journal-title":"J AOAC Int"},{"issue":"3","key":"7659_CR78","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/trstmh\/tru011","volume":"108","author":"C Rocio","year":"2014","unstructured":"Rocio C, Amato VS, Camargo RA, Tuon FF, Nicodemo AC (2014) Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients. Trans R Soc Trop Med Hyg 108(3):176\u2013178. https:\/\/doi.org\/10.1093\/trstmh\/tru011","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7659_CR79","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fcimb.2019.00353","volume":"9","author":"MM Romanelli","year":"2019","unstructured":"Romanelli MM et al (2019) Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis. Front Cell Infect Microbiol 9:353. https:\/\/doi.org\/10.3389\/fcimb.2019.00353","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"7659_CR80","doi-asserted-by":"publisher","first-page":"e17376","DOI":"10.1371\/journal.pone.0017376","volume":"6","author":"J Roychoudhury","year":"2011","unstructured":"Roychoudhury J, Sinha R, Ali N (2011) Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB\/c mice. PLoS ONE 6(3):e17376. https:\/\/doi.org\/10.1371\/journal.pone.0017376","journal-title":"PLoS ONE"},{"key":"7659_CR81","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2147\/IJN.S36654","volume":"9","author":"V Sanna","year":"2014","unstructured":"Sanna V, Pala N, Sechi M (2014) Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine 9:467\u2013483. https:\/\/doi.org\/10.2147\/IJN.S36654","journal-title":"Int J Nanomedicine"},{"issue":"10","key":"7659_CR82","first-page":"562","volume":"17","author":"J Santos","year":"2000","unstructured":"Santos J, Rivero A, Marquez M (2000) Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection. An Med Interna 17(10):562\u2013563","journal-title":"An Med Interna"},{"issue":"1\u20132","key":"7659_CR83","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijpharm.2006.01.048","volume":"315","author":"DA Schettini","year":"2006","unstructured":"Schettini DA et al (2006) Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. Int J Pharm 315(1\u20132):140\u2013147. https:\/\/doi.org\/10.1016\/j.ijpharm.2006.01.048","journal-title":"Int J Pharm"},{"key":"7659_CR84","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-0-387-76713-0_9","volume":"620","author":"RA Schwendener","year":"2007","unstructured":"Schwendener RA (2007) Liposomes in biology and medicine. Adv Exp Med Biol 620:117\u2013128. https:\/\/doi.org\/10.1007\/978-0-387-76713-0_9","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"7659_CR85","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijantimicag.2010.03.008","volume":"36","author":"R Sen","year":"2010","unstructured":"Sen R, Ganguly S, Saha P, Chatterjee M (2010) Efficacy of artemisinin in experimental visceral leishmaniasis. Int J Antimicrob Agents 36(1):43\u201349. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.03.008","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"7659_CR86","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1021\/acs.molpharmaceut.8b00097","volume":"15","author":"L Smith","year":"2018","unstructured":"Smith L, Serrano DR, Mauger M, Bolas-Fernandez F, Dea-Ayuela MA, Lalatsa A (2018) Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis. Mol Pharm 15(7):2570\u20132583. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00097","journal-title":"Mol Pharm"},{"issue":"2","key":"7659_CR87","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0974-777X.62886","volume":"2","author":"S Sundar","year":"2010","unstructured":"Sundar S, Chakravarty J (2010) Liposomal amphotericin B and leishmaniasis: dose and response. J Glob Infect Dis 2(2):159\u2013166. https:\/\/doi.org\/10.4103\/0974-777X.62886","journal-title":"J Glob Infect Dis"},{"issue":"3","key":"7659_CR88","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/bcpt.12990","volume":"123","author":"GSV Tavares","year":"2018","unstructured":"Tavares GSV et al (2018) Antileishmanial Activity, Cytotoxicity and Mechanism of Action of Clioquinol Against Leishmania infantum and Leishmania amazonensis Species. Basic Clin Pharmacol Toxicol 123(3):236\u2013246. https:\/\/doi.org\/10.1111\/bcpt.12990","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"7659_CR89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.parint.2018.10.005","volume":"68","author":"GSV Tavares","year":"2019","unstructured":"Tavares GSV et al (2019) A Pluronic(R) F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection. Parasitol Int 68(1):63\u201372. https:\/\/doi.org\/10.1016\/j.parint.2018.10.005","journal-title":"Parasitol Int"},{"issue":"10","key":"7659_CR90","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1128\/AAC.00671-11","volume":"55","author":"VM Taylor","year":"2011","unstructured":"Taylor VM et al (2011) In vitro and in vivo studies of the utility of dimethyl and diethyl carbaporphyrin ketals in treatment of cutaneous leishmaniasis. Antimicrob Agents Chemother 55(10):4755\u20134764. https:\/\/doi.org\/10.1128\/AAC.00671-11","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"7659_CR91","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1590\/s0036-46652008000300005","volume":"50","author":"AC Teixeira","year":"2008","unstructured":"Teixeira AC, Paes MG, Guerra Jde O, Prata A, Silva-Vergara ML (2008) Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Rev Inst Med Trop Sao Paulo 50(3):157\u2013160. https:\/\/doi.org\/10.1590\/s0036-46652008000300005","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"2","key":"7659_CR92","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijantimicag.2010.04.006","volume":"36","author":"AG Tempone","year":"2010","unstructured":"Tempone AG, Mortara RA, de Andrade HF Jr, Reimao JQ (2010) Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis. Int J Antimicrob Agents 36(2):159\u201363. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.04.006","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"7659_CR93","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1086\/517848","volume":"44","author":"FF Tuon","year":"2007","unstructured":"Tuon FF, Amato VS (2007) Mucosal leishmaniasis and miltefosine. Clin Infect Dis 44(11):1525\u20136. https:\/\/doi.org\/10.1086\/517848 (author reply 1526-7)","journal-title":"Clin Infect Dis"},{"issue":"5","key":"7659_CR94","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1590\/S0036-46652008000500013","volume":"50","author":"FF Tuon","year":"2008","unstructured":"Tuon FF, Amato VS (2008) Neglected tropical diseases: beyond the wars. Rev Inst Med Trop Sao Paulo 50(5):313\u2013314. https:\/\/doi.org\/10.1590\/S0036-46652008000500013","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"2","key":"7659_CR95","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-4632.2009.03982.x","volume":"48","author":"FF Tuon","year":"2009","unstructured":"Tuon FF, Amato VS (2009) Systematic review of New World cutaneous leishmaniasis: few points to be applied to Old World leishmaniasis. Int J Dermatol 48(2):201\u2013202. https:\/\/doi.org\/10.1111\/j.1365-4632.2009.03982.x","journal-title":"Int J Dermatol"},{"issue":"2","key":"7659_CR96","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1365-4632.2008.03417.x","volume":"47","author":"FF Tuon","year":"2008","unstructured":"Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC, Amato Neto V (2008) Treatment of New World cutaneous leishmaniasis\u2013a systematic review with a meta-analysis. Int J Dermatol 47(2):109\u2013124. https:\/\/doi.org\/10.1111\/j.1365-4632.2008.03417.x","journal-title":"Int J Dermatol"},{"key":"7659_CR97","doi-asserted-by":"publisher","first-page":"107934","DOI":"10.1016\/j.exppara.2020.107934","volume":"217","author":"JR Valentim Silva","year":"2020","unstructured":"Valentim Silva JR et al (2020) A natural cell-penetrating nanopeptide combined with pentavalent antimonial as experimental therapy against cutaneous leishmaniasis. Exp Parasitol 217:107934. https:\/\/doi.org\/10.1016\/j.exppara.2020.107934","journal-title":"Exp Parasitol"},{"issue":"4","key":"7659_CR98","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4269\/ajtmh.1997.57.403","volume":"57","author":"JE Valladares","year":"1997","unstructured":"Valladares JE, Freixas J, Alberola J, Franquelo C, Cristofol C, Arboix M (1997) Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs. Am J Trop Med Hyg 57(4):403\u2013406. https:\/\/doi.org\/10.4269\/ajtmh.1997.57.403","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"7659_CR99","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1021\/acsbiomaterials.0c01132","volume":"7","author":"DM Varma","year":"2021","unstructured":"Varma DM, Redding EA, Bachelder EM, Ainslie KM (2021) Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis. ACS Biomater Sci Eng 7(5):1725\u20131741. https:\/\/doi.org\/10.1021\/acsbiomaterials.0c01132","journal-title":"ACS Biomater Sci Eng"},{"issue":"5","key":"7659_CR100","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1128\/AAC.34.5.918","volume":"34","author":"JL Vennerstrom","year":"1990","unstructured":"Vennerstrom JL, Lovelace JK, Waits VB, Hanson WL, Klayman DL (1990) Berberine derivatives as antileishmanial drugs. Antimicrob Agents Chemother 34(5):918\u2013921. https:\/\/doi.org\/10.1128\/AAC.34.5.918","journal-title":"Antimicrob Agents Chemother"},{"key":"7659_CR101","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2147\/IJN.S106548","volume":"12","author":"MY Want","year":"2017","unstructured":"Want MY et al (2017) Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis. Int J Nanomedicine 12:2189\u20132204. https:\/\/doi.org\/10.2147\/IJN.S106548","journal-title":"Int J Nanomedicine"},{"issue":"11","key":"7659_CR102","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3109\/03639049809089944","volume":"24","author":"B Wolf","year":"1998","unstructured":"Wolf B (1998) Hydrophilic-lipophilic drug carrier systems of bead cellulose and isopropyl myristate. Drug Dev Ind Pharm 24(11):1007\u20131015. https:\/\/doi.org\/10.3109\/03639049809089944","journal-title":"Drug Dev Ind Pharm"},{"issue":"38","key":"7659_CR103","doi-asserted-by":"publisher","first-page":"39925","DOI":"10.1074\/jbc.M405635200","volume":"279","author":"S Wyllie","year":"2004","unstructured":"Wyllie S, Cunningham ML, Fairlamb AH (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279(38):39925\u201339932. https:\/\/doi.org\/10.1074\/jbc.M405635200","journal-title":"J Biol Chem"},{"issue":"Pt 1","key":"7659_CR104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/s0031182000074758","volume":"106","author":"DM Yang","year":"1993","unstructured":"Yang DM, Liew FY (1993) Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasis. Parasitology 106(Pt 1):7\u201311. https:\/\/doi.org\/10.1017\/s0031182000074758","journal-title":"Parasitology"},{"issue":"1","key":"7659_CR105","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/09546634.2015.1054778","volume":"27","author":"Y Yesilova","year":"2016","unstructured":"Yesilova Y et al (2016) Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis. J Dermatolog Treat 27(1):83\u201387. https:\/\/doi.org\/10.3109\/09546634.2015.1054778","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"7659_CR106","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00436-010-1906-y","volume":"107","author":"R Zhang","year":"2010","unstructured":"Zhang R et al (2010) In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani. Parasitol Res 107(2):475\u2013479. https:\/\/doi.org\/10.1007\/s00436-010-1906-y","journal-title":"Parasitol Res"}],"container-title":["Parasitology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-022-07659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00436-022-07659-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-022-07659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T18:06:16Z","timestamp":1665597976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00436-022-07659-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":106,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7659"],"URL":"https:\/\/doi.org\/10.1007\/s00436-022-07659-5","relation":{},"ISSN":["0932-0113","1432-1955"],"issn-type":[{"value":"0932-0113","type":"print"},{"value":"1432-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"assertion":[{"value":"29 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"F. F. Tuon is a CNPq researcher. The other authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}